Participants 22 166 7
f macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)
Participants 211 313 7
Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke
Participants 487 610 6
to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes.
Participants 672 748 5
5238 patients with type 2 diabetes who had evidence of macrovascular disease
Participants 753 814 3
recruited patients from primary-care practices and hospitals.
Participants 1549 1735 4
514 of 2605 patients in the pioglitazone group and 572 of 2633 patients in the placebo group had at least one event in the primary composite endpoint (HR 0.90, 95% CI 0.80-1.02, p=0.095)
Participants 1852 1941 3
301 patients in the pioglitazone group and 358 in the placebo group reached this endpoint
Participants 2323 2485 6
s the composite of all-cause mortality, non-fatal myocardial infarction, and stroke in patients with type 2 diabetes who have a high risk of macrovascular events.
